Latest Cancer stem cell Stories
- Data supports potential to address a significant unmet need as a therapeutic option for temozolomide-resistant GBM - VANCOUVER, British Columbia and MENLO PARK, Calif., April 20, 2015 /PRNewswire/
-- Animal model highly representative of late-stage ovarian cancer in women PHILADEPHIA, April 20, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Ltd, (ASX:NRT;
DETROIT, April 13, 2015 /PRNewswire/ -- The 2015 Henry Ford Brain Tumor Symposium takes place 8 a.m. - 5 p.m.
Discovery opens door to novel, small-molecule therapies for osteosarcoma NEW YORK, April 2, 2015 /PRNewswire-USNewswire/ -- A particular molecular pathway permits stem cells in pediatric
Key data confirming Cantrixil kills ovarian cancer stem cells SYDNEY, March 30, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ:NVGN) and
The show can be heard in the greater Los Angeles area Sundays @ 4pm PST on TalkRadio 790 KABC, or worldwide on KABC.com or the KABC app – available on the App Store or Google Play.
The 5th World Congress on Cell and Stem Cell Research in Chicago was opened yesterday by two presentations from Boston stem cell biotechnology start-up company Asymmetrex.
At the upcoming 5th World Congress on Cell and Stem Cell Research, taking place in Chicago next week (March 23-25), Asymmetrex, LLC will lead the symposium on Stem Cell Medical Engineering.
SYDNEY, March 18, 2015 /PRNewswire/ -- Novogen announced on 18(th) March, 2015 that one of its oncology pipeline drug candidates, Anisina (ATM-3507), has achieved a major milestone in its development,
SYDNEY, March 6, 2015 /PRNewswire/ -- Novogen today announces that Professor Gil Mor MD PhD from Yale Medical School will be presenting pre-clinical data on the lead candidate product, Cantrixil,
- Growing in low tufty patches.